Yunuen Avalos-Padilla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yunuen Avalos-Padilla has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Xavier Fernàndez-Busquets
Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain
12 shared publications - Rumiana Dimova
Max Planck Institute of Colloids and Interfaces, Science Park Golm, 14476 Potsdam, Germany
4 shared publications Vasil N. Georgiev
Department of Theory and Bio-Systems, Max Planck Institute of Colloids and Interfaces
4 shared publications- Diego Muñoz-Torrero
Laboratory of Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain
3 shared publications - Esther Orozco
Departamento de Infectómica y Patogénesis Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (IPN), Ciudad de México, Mexico
3 shared publications - Valentín Iglesias
Institut de Biotecnologia i Biomedicina and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain
3 shared publications
Latest Publications
- Open Access
- 26 June 2026
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 15 (1) , 2686468
Extracellular vesicles participate in proteostasis and heat shock adaptation in Plasmodium falciparum
In 2024, malaria remained a major global health burden, with an estimated 270 million cases and 610,000 deaths [1]. The disease is caused by protozoan parasites of the genus Plasmodium, among which...
- 26 June 2026
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 15 (1) , 2686468
Open AccessExtracellular vesicles participate in proteostasis and heat shock adaptation in Plasmodium falciparum
In 2024, malaria remained a major global health burden, with an estimated 270 million cases and 610,000 deaths [1]. The disease is caused by protozoan parasites of the genus Plasmodium, among which...
- Open Access
- 13 May 2026
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 26 (12) , 3762-3769
Creating an improved workflow for paper-based malaria diagnostics by integrating total lysis of whole blood
Detection of parasite biomarkers is critical for diagnosis and treatment monitoring; however, proper analysis of whole blood samples typically requires red blood cell lysis. While lysis is easily achieved in laboratory environments, there is a clinical need for low-cost technology to collect, process, and analyze these samples in low-resource settings. Dried blood spot cards offer a simple way to microsample blood in these settings, but standard cards cannot perform sample preprocessing, including the required lysis step. To meet this need, we have developed a three-dimensional paper-based lysis device that was fabricated alternatively by laser cutting and by wax-printing. This device effectively achieved 100% cellular lysis independent of sample composition. Successful lysis from these devices resulted in the detection of a malaria biomarker comparable to the standard liquid lysis procedure of Plasmodium-infected samples. Moreover, if device-dried, samples displayed antigen stability for over 1 week at room temperature, which facilitated delayed laboratory testing as well. The results show that these lysis devices have the potential to expand the types of environments from which samples tested for malaria can be collected.
- 13 May 2026
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 26 (12) , 3762-3769
Open AccessCreating an improved workflow for paper-based malaria diagnostics by integrating total lysis of whole blood
Detection of parasite biomarkers is critical for diagnosis and treatment monitoring; however, proper analysis of whole blood samples typically requires red blood cell lysis. While lysis is easily achieved in laboratory environments, there is a clinical need for low-cost technology to collect, process, and analyze these samples in low-resource settings. Dried blood spot cards offer a simple way to microsample blood in these settings, but standard cards cannot perform sample preprocessing, including the required lysis step. To meet this need, we have developed a three-dimensional paper-based lysis device that was fabricated alternatively by laser cutting and by wax-printing. This device effectively achieved 100% cellular lysis independent of sample composition. Successful lysis from these devices resulted in the detection of a malaria biomarker comparable to the standard liquid lysis procedure of Plasmodium-infected samples. Moreover, if device-dried, samples displayed antigen stability for over 1 week at room temperature, which facilitated delayed laboratory testing as well. The results show that these lysis devices have the potential to expand the types of environments from which samples tested for malaria can be collected.
- Open Access
- 28 February 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (3) , 304
Development of DNA Aptamers Against Leishmania infantum GP63 Protein for Therapeutic and Diagnostic Applications
Background/Objectives: Leishmaniasis is a disease affecting millions of people caused by parasites of the genus Leishmania. The GP63 protein of Leishmania infantum (LiGP63) is one of its major surface antigens and a main virulence factor, playing a role in the adhesion of extracellular promastigote stages to macrophages and in the survival of intracellular amastigotes. Methods: Here, DNA aptamers have been developed against LiGP63 through the systematic evolution of ligands by exponential enrichment. Results: Twenty individual aptamer sequences were characterized using confocal fluorescence microscopy and flow cytometry analysis, and 14 of them had targeting to more than 70% of L. infantum promastigotes with different subcellular localization patterns. Subsequent dot blot analyses narrowed down the selection to five candidates for further characterization through an aptamer-linked immobilized sorbent assay where it was possible to detect endogenous LiGP63 in L. infantum promastigote lysates. The five selected aptamers recognized the recombinant LiGP63 protein with binding affinities ranging from 0.3 to 2.1 µM. Promastigotes preincubated with LiGP63Apt-4, -27 and -28 exhibited a significantly reduced adhesion to and infection of RAW 264.7 macrophages. Moreover, when LiGP63Apt-4 and -28 were conjugated to liposomes, these two aptamers significantly enhanced the targeting to L. infantum promastigotes compared to plain liposomes. Conclusions: Given their improved stability and cost-effectiveness over antibodies, the aptamers evolved here represent promising candidates for new therapeutic and diagnostic approaches and for future nanoparticle-based drug delivery strategies in leishmaniasis.
- 28 February 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (3) , 304
Open AccessDevelopment of DNA Aptamers Against Leishmania infantum GP63 Protein for Therapeutic and Diagnostic Applications
Background/Objectives: Leishmaniasis is a disease affecting millions of people caused by parasites of the genus Leishmania. The GP63 protein of Leishmania infantum (LiGP63) is one of its major surface antigens and a main virulence factor, playing a role in the adhesion of extracellular promastigote stages to macrophages and in the survival of intracellular amastigotes. Methods: Here, DNA aptamers have been developed against LiGP63 through the systematic evolution of ligands by exponential enrichment. Results: Twenty individual aptamer sequences were characterized using confocal fluorescence microscopy and flow cytometry analysis, and 14 of them had targeting to more than 70% of L. infantum promastigotes with different subcellular localization patterns. Subsequent dot blot analyses narrowed down the selection to five candidates for further characterization through an aptamer-linked immobilized sorbent assay where it was possible to detect endogenous LiGP63 in L. infantum promastigote lysates. The five selected aptamers recognized the recombinant LiGP63 protein with binding affinities ranging from 0.3 to 2.1 µM. Promastigotes preincubated with LiGP63Apt-4, -27 and -28 exhibited a significantly reduced adhesion to and infection of RAW 264.7 macrophages. Moreover, when LiGP63Apt-4 and -28 were conjugated to liposomes, these two aptamers significantly enhanced the targeting to L. infantum promastigotes compared to plain liposomes. Conclusions: Given their improved stability and cost-effectiveness over antibodies, the aptamers evolved here represent promising candidates for new therapeutic and diagnostic approaches and for future nanoparticle-based drug delivery strategies in leishmaniasis.
- Open Access
Liquid-liquid phase separation (LLPS) as a sensing and adaptation mechanism: An evidence-based hypothesis on AP2 transcription factors in the malaria parasite
Background: Protein liquid-liquid phase separation (LLPS) can be driven by prion-like domains (PrLDs) inside intrinsically disordered regions (IDRs). The causing agent of the deadliest form of human malaria, Plasmodium falciparum, has abundant prion-like proteins whose aggregation is presumed to have a functional role. Multiple members of the largest family of transcription factors in P. falciparum, AP2 (PfAP2), responsible for adapting the parasite gene response in different scenarios, were found in aggregation-prone protein screenings. Results: We show that the PfAP2s members carry the physicochemical determinants to perform LLPS forming biomolecular condensates in vivo. The long IDRs of PfAP2s could sense changes in the cellular microenvironment, and their PrLDs could drive conformational rearrangements. PfAP2s do not function as centralizing hubs for protein-protein interaction networks, but display significant preferred interactions among themselves, establishing a large, connected subnetwork. Predictions suggest that all PfAP2s have regions to localize into LLPS-condensates, while larger PfAP2s could initiate condensation. We show that four PfAP2 members co-localize in live P. falciparum, bearing the potential to be engaged in LLPS-condensates. Conclusion: We present bioinformatics analyses and experimental data obtained in live parasites suggesting that PfAP2s are able to direct LLPS in P. falciparum. We propose a model in which sensing by the parasite of cellular stresses like host transfer, temperature changes and energy depletion, and the corresponding gene responses are driven by LLPS where the PfAP2 family plays a fundamental role. Finally, we postulate targeting PfAP2 as a new therapeutic antimalarial strategy to curb the emergence of drug-resistant parasites.
Open AccessLiquid-liquid phase separation (LLPS) as a sensing and adaptation mechanism: An evidence-based hypothesis on AP2 transcription factors in the malaria parasite
Background: Protein liquid-liquid phase separation (LLPS) can be driven by prion-like domains (PrLDs) inside intrinsically disordered regions (IDRs). The causing agent of the deadliest form of human malaria, Plasmodium falciparum, has abundant prion-like proteins whose aggregation is presumed to have a functional role. Multiple members of the largest family of transcription factors in P. falciparum, AP2 (PfAP2), responsible for adapting the parasite gene response in different scenarios, were found in aggregation-prone protein screenings. Results: We show that the PfAP2s members carry the physicochemical determinants to perform LLPS forming biomolecular condensates in vivo. The long IDRs of PfAP2s could sense changes in the cellular microenvironment, and their PrLDs could drive conformational rearrangements. PfAP2s do not function as centralizing hubs for protein-protein interaction networks, but display significant preferred interactions among themselves, establishing a large, connected subnetwork. Predictions suggest that all PfAP2s have regions to localize into LLPS-condensates, while larger PfAP2s could initiate condensation. We show that four PfAP2 members co-localize in live P. falciparum, bearing the potential to be engaged in LLPS-condensates. Conclusion: We present bioinformatics analyses and experimental data obtained in live parasites suggesting that PfAP2s are able to direct LLPS in P. falciparum. We propose a model in which sensing by the parasite of cellular stresses like host transfer, temperature changes and energy depletion, and the corresponding gene responses are driven by LLPS where the PfAP2 family plays a fundamental role. Finally, we postulate targeting PfAP2 as a new therapeutic antimalarial strategy to curb the emergence of drug-resistant parasites.
- Open Access
- 13 May 2025
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 15, 1565814
Overexpression in Plasmodium falciparum of an intrinsically disordered protein segment of PfUT impairs the parasite’s proteostasis and reduces its growth rate
The proteome of Plasmodium falciparum exhibits a marked propensity for aggregation. This characteristic results from the parasite’s AT-rich genome, which encodes numerous proteins with long asparagine-rich stretches and low structural complexity, which lead to abundant intrinsically disordered regions. While this poses challenges for the parasite, the propensity for protein aggregation may also serve functional roles, such as stress adaptation, and could therefore be exploited by targeting it as a potential vulnerable spot in the pathogen. Here, we overexpressed an aggregation-prone segment of the P. falciparum ubiquitin transferase (PfUTf), an E3 ubiquitin ligase protein that has been previously demonstrated to regulate the stability of parasite proteins involved in invasion, development and drug metabolism. Overexpression of PfUTf in P. falciparum had evident phenotypic effects observed by transmission electron microscopy and confocal fluorescence microscopy, increased endogenous protein aggregation, disrupted proteostasis, and caused significant growth impairment in the parasite. Combined with dihydroartemisinin treatment, PfUTf overexpression had a synergistic effect that further compromised the parasite´s viability, linking protein aggregation to proteasome dysfunction. Changes in the distribution of aggregation-prone proteins, shown by the altered subcellular fluorescent pattern of the new investigational aggregated protein dye and antiplasmodial compound YAT2150 in the overexpressing P. falciparum line, highlighted the critical balance between protein aggregation, stress responses, and parasite viability, suggesting proteostasis-targeting therapies as a good antimalarial strategy.
- 13 May 2025
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 15, 1565814
Open AccessOverexpression in Plasmodium falciparum of an intrinsically disordered protein segment of PfUT impairs the parasite’s proteostasis and reduces its growth rate
The proteome of Plasmodium falciparum exhibits a marked propensity for aggregation. This characteristic results from the parasite’s AT-rich genome, which encodes numerous proteins with long asparagine-rich stretches and low structural complexity, which lead to abundant intrinsically disordered regions. While this poses challenges for the parasite, the propensity for protein aggregation may also serve functional roles, such as stress adaptation, and could therefore be exploited by targeting it as a potential vulnerable spot in the pathogen. Here, we overexpressed an aggregation-prone segment of the P. falciparum ubiquitin transferase (PfUTf), an E3 ubiquitin ligase protein that has been previously demonstrated to regulate the stability of parasite proteins involved in invasion, development and drug metabolism. Overexpression of PfUTf in P. falciparum had evident phenotypic effects observed by transmission electron microscopy and confocal fluorescence microscopy, increased endogenous protein aggregation, disrupted proteostasis, and caused significant growth impairment in the parasite. Combined with dihydroartemisinin treatment, PfUTf overexpression had a synergistic effect that further compromised the parasite´s viability, linking protein aggregation to proteasome dysfunction. Changes in the distribution of aggregation-prone proteins, shown by the altered subcellular fluorescent pattern of the new investigational aggregated protein dye and antiplasmodial compound YAT2150 in the overexpressing P. falciparum line, highlighted the critical balance between protein aggregation, stress responses, and parasite viability, suggesting proteostasis-targeting therapies as a good antimalarial strategy.
- Open Access
- 22 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 3962
Extracellular Vesicle Abundance, but Not a High Aggregation-Prone Peptide Cargo, Is Associated with Dihydroartemisinin Exposure in Plasmodium falciparum
Our understanding of the molecular mechanisms undergirding artemisinin (ART) resistance in Plasmodium falciparum is currently based on two organizing principles: reduced hemoglobin trafficking into the digestive food vacuole, resulting in lower levels of activated ART, and increased tolerance to ART-induced oxidative stress in the infected erythrocyte. We had previously proposed an extracellular vesicle (EV) export model of ART resistance in P. falciparum. This model predicts that EV abundance will be altered by ART exposure and that the peptide cargo of EVs from the ART-exposed condition will be enriched with aggregation-prone peptides. We tested the predictions of the EV export hypothesis in this study using in vitro culture assays of an ART-resistant transgenic line engineered on a 3D7 background (R561H) and a 3D7 knock-out line (PfVps60KO) with deficient EV production phenotype. EV enrichment was obtained from in vitro parasite culture supernatants via a series of ultracentrifugation and filtration steps, followed by size exclusion chromatography. A quality check on EVs was performed using dynamic light scattering. Liquid chromatography with tandem mass spectrometry was used to determine the proteome cargo from extracted EVs, and parasite peptides were queried for aggregation-prone tendency using open-access software. We report that dihydroartemisinin (DHA) exposure was positively correlated with EV abundance (coefficient estimate = 1038.58, confidence interval of 194.86–1882.30, and p-value = 0.018) and suggests that EV biogenesis is part of the parasite’s response to DHA/ART. Furthermore, our findings suggest the expression of a non-constitutive DHA-induced alternate EV biogenesis pathway as the PfVps60KO was observed to produce the highest number of EVs under DHA exposure. Finally, we show that EVs from both ART-susceptible and resistant parasites under DHA exposure carry a cargo of Chorein N-terminal domain-containing protein (PF3D7_1021700) with a high aggregation-prone index (prion-like domain [PrLD] score = 26.5) out of nine identified parasite peptides. The former of these findings is in concordance with the EV export hypothesis, which posits that the removal of DHA/ART-induced aggregated and/or misfolded peptides is critical to the parasite’s survival under DHA/ART exposure. This observation further implicates EVs in the development of the ART-resistant phenotype. However, the finding of one aggregation-prone peptide out of the nine parasite proteins in the EV cargo does not sufficiently support the EV export hypothesis. Future replicates of this study and further interrogations of the EV export hypothesis are needed.
- 22 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 3962
Open AccessExtracellular Vesicle Abundance, but Not a High Aggregation-Prone Peptide Cargo, Is Associated with Dihydroartemisinin Exposure in Plasmodium falciparum
Our understanding of the molecular mechanisms undergirding artemisinin (ART) resistance in Plasmodium falciparum is currently based on two organizing principles: reduced hemoglobin trafficking into the digestive food vacuole, resulting in lower levels of activated ART, and increased tolerance to ART-induced oxidative stress in the infected erythrocyte. We had previously proposed an extracellular vesicle (EV) export model of ART resistance in P. falciparum. This model predicts that EV abundance will be altered by ART exposure and that the peptide cargo of EVs from the ART-exposed condition will be enriched with aggregation-prone peptides. We tested the predictions of the EV export hypothesis in this study using in vitro culture assays of an ART-resistant transgenic line engineered on a 3D7 background (R561H) and a 3D7 knock-out line (PfVps60KO) with deficient EV production phenotype. EV enrichment was obtained from in vitro parasite culture supernatants via a series of ultracentrifugation and filtration steps, followed by size exclusion chromatography. A quality check on EVs was performed using dynamic light scattering. Liquid chromatography with tandem mass spectrometry was used to determine the proteome cargo from extracted EVs, and parasite peptides were queried for aggregation-prone tendency using open-access software. We report that dihydroartemisinin (DHA) exposure was positively correlated with EV abundance (coefficient estimate = 1038.58, confidence interval of 194.86–1882.30, and p-value = 0.018) and suggests that EV biogenesis is part of the parasite’s response to DHA/ART. Furthermore, our findings suggest the expression of a non-constitutive DHA-induced alternate EV biogenesis pathway as the PfVps60KO was observed to produce the highest number of EVs under DHA exposure. Finally, we show that EVs from both ART-susceptible and resistant parasites under DHA exposure carry a cargo of Chorein N-terminal domain-containing protein (PF3D7_1021700) with a high aggregation-prone index (prion-like domain [PrLD] score = 26.5) out of nine identified parasite peptides. The former of these findings is in concordance with the EV export hypothesis, which posits that the removal of DHA/ART-induced aggregated and/or misfolded peptides is critical to the parasite’s survival under DHA/ART exposure. This observation further implicates EVs in the development of the ART-resistant phenotype. However, the finding of one aggregation-prone peptide out of the nine parasite proteins in the EV cargo does not sufficiently support the EV export hypothesis. Future replicates of this study and further interrogations of the EV export hypothesis are needed.
- Open Access
- 30 September 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (10) , 1290
Leveraging the Aggregated Protein Dye YAT2150 for Malaria Chemotherapy
Background/Objectives: YAT2150 is a first-in-class antiplasmodial compound that has been recently proposed as a new interesting drug for malaria therapy. Methods/Results: The fluorescence of YAT2150 rapidly increases upon its entry into Plasmodium, a property that can be of use for the design of highly sensitive diagnostic approaches. YAT2150 blocks the in vitro development of the ookinete stage of Plasmodium and, when added to an infected blood meal, inhibits oocyst formation in the mosquito. Thus, the compound could possibly contribute to future transmission-blocking antimalarial strategies. Cell influx/efflux studies in Caco-2 cells suggest that YAT2150 is internalized by endocytosis and also through the OATP2B1 transporter, whereas its main export route would be via OSTα. YAT2150 has an overall favorable drug metabolism and pharmacokinetics profile, and its moderate cytotoxicity can be significantly reduced upon encapsulation in immunoliposomes, which leads to a dramatic increase in the drug selectivity index to values close to 1000. Although YAT2150 binds amyloid-forming peptides, its in vitro fluorescence emission is stronger upon association with peptides that form amorphous aggregates, suggesting that regions enriched in unstructured proteins are the preferential binding sites of the drug inside Plasmodium cells. The reduction of protein aggregation in the parasite after YAT2150 treatment, which has been suggested to be directly related to the drug’s mode of action, is also observed following treatment with quinoline antimalarials like chloroquine and primaquine. Conclusions: Altogether, the data presented here indicate that YAT2150 can represent the spearhead of a new family of compounds for malaria diagnosis and therapy due to its presumed novel mode of action based on the interaction with functional protein aggregates in the pathogen.
- 30 September 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (10) , 1290
Open AccessLeveraging the Aggregated Protein Dye YAT2150 for Malaria Chemotherapy
Background/Objectives: YAT2150 is a first-in-class antiplasmodial compound that has been recently proposed as a new interesting drug for malaria therapy. Methods/Results: The fluorescence of YAT2150 rapidly increases upon its entry into Plasmodium, a property that can be of use for the design of highly sensitive diagnostic approaches. YAT2150 blocks the in vitro development of the ookinete stage of Plasmodium and, when added to an infected blood meal, inhibits oocyst formation in the mosquito. Thus, the compound could possibly contribute to future transmission-blocking antimalarial strategies. Cell influx/efflux studies in Caco-2 cells suggest that YAT2150 is internalized by endocytosis and also through the OATP2B1 transporter, whereas its main export route would be via OSTα. YAT2150 has an overall favorable drug metabolism and pharmacokinetics profile, and its moderate cytotoxicity can be significantly reduced upon encapsulation in immunoliposomes, which leads to a dramatic increase in the drug selectivity index to values close to 1000. Although YAT2150 binds amyloid-forming peptides, its in vitro fluorescence emission is stronger upon association with peptides that form amorphous aggregates, suggesting that regions enriched in unstructured proteins are the preferential binding sites of the drug inside Plasmodium cells. The reduction of protein aggregation in the parasite after YAT2150 treatment, which has been suggested to be directly related to the drug’s mode of action, is also observed following treatment with quinoline antimalarials like chloroquine and primaquine. Conclusions: Altogether, the data presented here indicate that YAT2150 can represent the spearhead of a new family of compounds for malaria diagnosis and therapy due to its presumed novel mode of action based on the interaction with functional protein aggregates in the pathogen.
- 1 March 2024
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 16 (2) , e1943
Nanotherapeutics against malaria: A decade of advancements in experimental models
Malaria, caused by different species of protists of the genus Plasmodium, remains among the most common causes of death due to parasitic diseases worldwide, mainly for children aged under 5. One of the main obstacles to malaria eradication is the speed with which the pathogen evolves resistance to the drug schemes developed against it. For this reason, it remains urgent to find innovative therapeutic strategies offering sufficient specificity against the parasite to minimize resistance evolution and drug side effects. In this context, nanotechnology‐based approaches are now being explored for their use as antimalarial drug delivery platforms due to the wide range of advantages and tuneable properties that they offer. However, major challenges remain to be addressed to provide a cost‐efficient and targeted therapeutic strategy contributing to malaria eradication. The present work contains a systematic review of nanotechnology‐based antimalarial drug delivery systems generated during the last 10 years.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease
- 1 March 2024
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 16 (2) , e1943
Nanotherapeutics against malaria: A decade of advancements in experimental models
Malaria, caused by different species of protists of the genus Plasmodium, remains among the most common causes of death due to parasitic diseases worldwide, mainly for children aged under 5. One of the main obstacles to malaria eradication is the speed with which the pathogen evolves resistance to the drug schemes developed against it. For this reason, it remains urgent to find innovative therapeutic strategies offering sufficient specificity against the parasite to minimize resistance evolution and drug side effects. In this context, nanotechnology‐based approaches are now being explored for their use as antimalarial drug delivery platforms due to the wide range of advantages and tuneable properties that they offer. However, major challenges remain to be addressed to provide a cost‐efficient and targeted therapeutic strategy contributing to malaria eradication. The present work contains a systematic review of nanotechnology‐based antimalarial drug delivery systems generated during the last 10 years.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease
- Open Access
- 6 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1163
In Vitro Evaluation of Aerosol Therapy with Pentamidine-Loaded Liposomes Coated with Chondroitin Sulfate or Heparin for the Treatment of Leishmaniasis
The second-line antileishmanial compound pentamidine is administered intramuscularly or, preferably, by intravenous infusion, with its use limited by severe adverse effects, including diabetes, severe hypoglycemia, myocarditis and renal toxicity. We sought to test the potential of phospholipid vesicles to improve the patient compliance and efficacy of this drug for the treatment of leishmaniasis by means of aerosol therapy. The targeting to macrophages of pentamidine-loaded liposomes coated with chondroitin sulfate or heparin increased about twofold (up to ca. 90%) relative to noncoated liposomes. The encapsulation of pentamidine in liposomes ameliorated its activity on the amastigote and promastigote forms of Leishmania infantum and Leishmania pifanoi, and it significantly reduced cytotoxicity on human umbilical endothelial cells, for which the concentration inhibiting 50% of cell viability was 144.2 ± 12.7 µM for pentamidine-containing heparin-coated liposomes vs. 59.3 ± 4.9 µM for free pentamidine. The deposition of liposome dispersions after nebulization was evaluated with the Next Generation Impactor, which mimics human airways. Approximately 53% of total initial pentamidine in solution reached the deeper stages of the impactor, with a median aerodynamic diameter of ~2.8 µm, supporting a partial deposition on the lung alveoli. Upon loading pentamidine in phospholipid vesicles, its deposition in the deeper stages significantly increased up to ~68%, and the median aerodynamic diameter decreased to a range between 1.4 and 1.8 µm, suggesting a better aptitude to reach the deeper lung airways in higher amounts. In all, nebulization of liposome-encapsulated pentamidine improved the bioavailability of this neglected drug by a patient-friendly delivery route amenable to self-administration, paving the way for the treatment of leishmaniasis and other infections where pentamidine is active.
- 6 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1163
Open AccessIn Vitro Evaluation of Aerosol Therapy with Pentamidine-Loaded Liposomes Coated with Chondroitin Sulfate or Heparin for the Treatment of Leishmaniasis
The second-line antileishmanial compound pentamidine is administered intramuscularly or, preferably, by intravenous infusion, with its use limited by severe adverse effects, including diabetes, severe hypoglycemia, myocarditis and renal toxicity. We sought to test the potential of phospholipid vesicles to improve the patient compliance and efficacy of this drug for the treatment of leishmaniasis by means of aerosol therapy. The targeting to macrophages of pentamidine-loaded liposomes coated with chondroitin sulfate or heparin increased about twofold (up to ca. 90%) relative to noncoated liposomes. The encapsulation of pentamidine in liposomes ameliorated its activity on the amastigote and promastigote forms of Leishmania infantum and Leishmania pifanoi, and it significantly reduced cytotoxicity on human umbilical endothelial cells, for which the concentration inhibiting 50% of cell viability was 144.2 ± 12.7 µM for pentamidine-containing heparin-coated liposomes vs. 59.3 ± 4.9 µM for free pentamidine. The deposition of liposome dispersions after nebulization was evaluated with the Next Generation Impactor, which mimics human airways. Approximately 53% of total initial pentamidine in solution reached the deeper stages of the impactor, with a median aerodynamic diameter of ~2.8 µm, supporting a partial deposition on the lung alveoli. Upon loading pentamidine in phospholipid vesicles, its deposition in the deeper stages significantly increased up to ~68%, and the median aerodynamic diameter decreased to a range between 1.4 and 1.8 µm, suggesting a better aptitude to reach the deeper lung airways in higher amounts. In all, nebulization of liposome-encapsulated pentamidine improved the bioavailability of this neglected drug by a patient-friendly delivery route amenable to self-administration, paving the way for the treatment of leishmaniasis and other infections where pentamidine is active.
- Open Access
- 19 November 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (11) , 2515
Selection of an Aptamer against the Enzyme 1-deoxy-D-xylulose-5-phosphate Reductoisomerase from Plasmodium falciparum
The methyl erythritol phosphate (MEP) pathway of isoprenoid biosynthesis is essential for malaria parasites and also for several human pathogenic bacteria, thus representing an interesting target for future antimalarials and antibiotics and for diagnostic strategies. We have developed a DNA aptamer (D10) against Plasmodium falciparum 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), the second enzyme of this metabolic route. D10 binds in vitro to recombinant DXR from P. falciparum and Escherichia coli, showing at 10 µM a ca. 50% inhibition of the bacterial enzyme. In silico docking analysis indicates that D10 associates with DXR in solvent-exposed regions outside the active center pocket. According to fluorescence confocal microscopy data, this aptamer specifically targets in P. falciparum in vitro cultures the apicoplast organelle where the MEP pathway is localized and is, therefore, a highly specific marker of red blood cells parasitized by Plasmodium vs. naïve erythrocytes. D10 is also selective for the detection of MEP+ bacteria (e.g., E. coli and Pseudomonas aeruginosa) vs. those lacking DXR (e.g., Enterococcus faecalis). Based on these results, we discuss the potential of DNA aptamers in the development of ligands that can outcompete the performance of the well-established antibody technology for future therapeutic and diagnostic approaches.
- 19 November 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (11) , 2515
Open AccessSelection of an Aptamer against the Enzyme 1-deoxy-D-xylulose-5-phosphate Reductoisomerase from Plasmodium falciparum
The methyl erythritol phosphate (MEP) pathway of isoprenoid biosynthesis is essential for malaria parasites and also for several human pathogenic bacteria, thus representing an interesting target for future antimalarials and antibiotics and for diagnostic strategies. We have developed a DNA aptamer (D10) against Plasmodium falciparum 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), the second enzyme of this metabolic route. D10 binds in vitro to recombinant DXR from P. falciparum and Escherichia coli, showing at 10 µM a ca. 50% inhibition of the bacterial enzyme. In silico docking analysis indicates that D10 associates with DXR in solvent-exposed regions outside the active center pocket. According to fluorescence confocal microscopy data, this aptamer specifically targets in P. falciparum in vitro cultures the apicoplast organelle where the MEP pathway is localized and is, therefore, a highly specific marker of red blood cells parasitized by Plasmodium vs. naïve erythrocytes. D10 is also selective for the detection of MEP+ bacteria (e.g., E. coli and Pseudomonas aeruginosa) vs. those lacking DXR (e.g., Enterococcus faecalis). Based on these results, we discuss the potential of DNA aptamers in the development of ligands that can outcompete the performance of the well-established antibody technology for future therapeutic and diagnostic approaches.